. 2019 Apr 3;8(3):221–225. doi: 10.1007/s13730-019-00397-1

Table 2.

Representative case series on PRS or RPGN with double-positive ANCA and anti-GBM Ab, and single-positive ANCA and/or single-positive anti-GBM-Ab

Authors [references #]	Serotype	Cases, n	Age	Male gender (%)	Lung hemorrhage (%)	Serum creatinine (mg/dL)	Renal survival at 1 year (%)	Patient survival at 1 year (%)	Relapse rate (%)
McAdoo et al. [3]	DP	37	64	38	38	3.5	53	83	22
	SP-ANCA	568	62	54	23	2.1	88	90	37
	SP-GBM Ab	41	58	46	40	3.1	44	87	0
Alchi et al. [9]	DP	9	69	44	44	NA	16	88	22
Alchi et al. [9]	SP-GBM Ab	34	52	44	38	NA	16	88	0
Srivastava et al. [13]	DP	9	59	33	56^a	9.1	0	100	11
	SP-ANCA	18	57	56	39^a	3.1	89	94	NA
	SP-GBM Ab	6	52	33	50^a	9.6	33	100	NA
Cui et al. [11]	DP	39	60	56	41	9.6	25	49	NA
Cui et al. [11]	SP-GBM Ab	137	37	73	47	9.5	73	80	NA
Zhao et al. [7]	DP	61	55	54	77	10.1	15	38	NA
Rutgers et al. [4]	DP^b	10	64	80	NA	10.3	10	79	NA
	SP-ANCA^b	98	63	67	NA	5.0	64	75	NA
	SP-GBM	13	52	39	NA	9.6	15	100	NA
Levy et al. [5]	DP	27	66	48	41	7.2	26	52	0
Levy et al. [12]	SP-GBM Ab	71	40	56	62	3.6	53	77	3

PRS pulmonary renal syndrome, RPGN rapidly progressive glomerulonephritis, DP double positive for ANCA and anti-GBM antibody, SP single positive

^aSeveral respiratory symptoms in addition to lung hemorrhage, i.e., pleurisy, nodules, cavities and infiltrates are included

^bIndividuals with positive PR3-ANCA are excluded from the study because of small numbers